Takata Munehisa, Matsumoto Isao, Tanaka Yusuke, Saito Daisuke, Yoshida Shuhei, Kakegawa Seiichi, Tamura Masaya, Takemura Hirofumi, Ikeda Hiroko
Dept. of Thoracic, Cardiovascular and General Surgery, Kanazawa University.
Gan To Kagaku Ryoho. 2017 Mar;44(3):239-242.
A 61-year-old woman with an abnormal radiograph shadow in her anterior mediastinum was admitted to our hospital and underwent an extended thymectomy. The pathological diagnosis of the tumor was a non-papillary adenocarcinoma of the thymus in pathological stage IV b using the Masaoka classification owing to mediastinal lymph node metastasis. We found parasternal lymph node metastases 5 months after her first operation, and subsequently, she underwent surgery and adjuvant radiotherapy. We found systemic lymph node metastases and metastatic lesions in distant organs, including her lungs, brain, and kidney 27 months after her first operation. Systemic chemotherapy, such as carboplatin plus paclitaxel and an ADOC regimen were not very effective, so we performed immunohistochemical staining of the primary thymic adenocarcinoma. The levels of both thymidylate synthase and dihydropyrimidine dehydrogenase were low; therefore, we started S-1 100mg/body (2 weeks of administration, 1 week of withdrawal)31 months after her first operation. She entered complete remission 6 months after the initiation of S-1. We surgically resected her solitary lung metastasis 13 months after initiation of S-1, and then continued the S-1 treatment. There was no recurrence for more than 2 years after the lung surgery. We believe that when the expression levels of thymidylate synthase or dihydropyrimidine dehydrogenase are low in cases of recurrent thymic adenocarcinoma, S-1 may be able to induce an effective response.
一名61岁女性因前纵隔X线片阴影异常入住我院,接受了扩大胸腺切除术。根据Masaoka分期,由于纵隔淋巴结转移,肿瘤的病理诊断为IV b期非乳头状胸腺腺癌。首次手术后5个月,我们发现了胸骨旁淋巴结转移,随后,她接受了手术及辅助放疗。首次手术后27个月,我们发现了全身淋巴结转移以及远处器官(包括肺、脑和肾)的转移病灶。卡铂联合紫杉醇等全身化疗以及ADOC方案效果不佳,因此我们对原发性胸腺腺癌进行了免疫组化染色。胸苷酸合成酶和二氢嘧啶脱氢酶水平均较低;因此,首次手术后31个月,我们开始给予S-1,剂量为100mg/体(给药2周,停药1周)。开始使用S-1 6个月后,她进入完全缓解期。开始使用S-1 13个月后,我们手术切除了她孤立的肺转移灶,然后继续S-1治疗。肺手术后2年多未复发。我们认为,在复发性胸腺腺癌病例中,当胸苷酸合成酶或二氢嘧啶脱氢酶的表达水平较低时,S-1可能能够诱导有效反应。